| Drug / Therapy | Comparing Single-Session Therapies for Chronic Pain |
| Indication | — |
| Decision Type | Clinical Trial |
| Trial Phase | Clinical Trial |
| ClinicalTrials.gov | NCT07008105 |
ProMIS Neurosciences (PMN) operates in the Misfolded Protein ALS/AD sector. The current BTS Score is 42 (Grade: D).
Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.
The Clinical Trial date for Comparing Single-Session Therapies for Chronic Pain by ProMIS Neurosciences (PMN) is scheduled for June 1, 2026. This is the target date for the FDA to make a decision on this application.
Comparing Single-Session Therapies for Chronic Pain is being developed by ProMIS Neurosciences for the treatment of its target indication. It is currently in Clinical Trial clinical trials.
If Comparing Single-Session Therapies for Chronic Pain receives FDA approval, ProMIS Neurosciences (PMN) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Clinical Trial date closely.
Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for PMN on DilutionWatch at dilutionwatch.com/stock/PMN.html.
You can view the full BiotechSigns company profile for ProMIS Neurosciences (PMN) at biotechsign.com/app/company/PMN, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.
This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSigns is not a registered investment advisor.